Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    September 2024
  1. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available


    May 2024
  2. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    PubMed     Abstract available


    April 2024
  3. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    PubMed     Abstract available


  4. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    PubMed     Abstract available


    March 2024
  5. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    PubMed     Abstract available


  6. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed     Abstract available


    January 2024
  7. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    PubMed     Abstract available


  8. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    PubMed     Abstract available


    December 2023
  9. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    PubMed     Abstract available


  10. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    PubMed     Abstract available


    November 2023
  11. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available


    October 2023
  12. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available


  13. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available


  14. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available


    September 2023
  15. KONEN JM, Rodriguez BL, Wu H, Fradette JJ, et al
    Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
    J Clin Invest. 2023;133:e163128.
    PubMed     Abstract available


    August 2023
  16. MALCHERS F, Nogova L, van Attekum MH, Maas L, et al
    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    J Clin Invest. 2023 Aug 22:e170217. doi: 10.1172/JCI170217.
    PubMed     Abstract available


    July 2023
  17. ATTIG J, Pape J, Doglio L, Kazachenka A, et al
    Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.
    J Clin Invest. 2023;133:e164397.
    PubMed     Abstract available


    June 2023
  18. NARDI F, Perurena N, Schade AE, Li ZH, et al
    Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer.
    J Clin Invest. 2023 Jun 29:e167651. doi: 10.1172/JCI167651.
    PubMed     Abstract available


    April 2023
  19. SALMON M, Alvarez-Diaz R, Fustero-Torre C, Brehey O, et al
    Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    J Clin Invest. 2023;133:e164413.
    PubMed     Abstract available


  20. HU Z, Yu X, Ding R, Liu B, et al
    Glycolysis drives STING signaling to facilitate dendritic cell antitumor function.
    J Clin Invest. 2023;133:e166031.
    PubMed     Abstract available


    March 2023
  21. JASPERS JE, Khan JF, Godfrey WD, Lopez AV, et al
    IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
    J Clin Invest. 2023 Mar 23:e166028. doi: 10.1172/JCI166028.
    PubMed     Abstract available


    February 2023
  22. TAN X, Xiao GY, Wang S, Shi L, et al
    EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
    J Clin Invest. 2023 Feb 9:e165863. doi: 10.1172/JCI165863.
    PubMed     Abstract available


    January 2023
  23. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
    J Clin Invest. 2023;133:e160330.
    PubMed     Abstract available


  24. HU H, Cheng R, Wang Y, Wang X, et al
    Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    J Clin Invest. 2023;133:e153470.
    PubMed     Abstract available


  25. DING L, Chen X, Zhang W, Dai X, et al
    Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
    J Clin Invest. 2023;133:e154754.
    PubMed     Abstract available


    December 2022
  26. ZHANG S, You X, Zheng Y, Shen Y, et al
    The UBE2C/CDH1/DEPTOR axis is an oncogene-tumor suppressor cascade in lung cancer cells.
    J Clin Invest. 2022 Dec 22:e162434. doi: 10.1172/JCI162434.
    PubMed     Abstract available


    November 2022
  27. LI K, Liu Y, Ding Y, Zhang Z, et al
    BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


  28. ZHANG H, Zhu X, Friesen TJ, Kwak JW, et al
    Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    September 2022
  29. NIE M, Chen N, Pang H, Jiang T, et al
    Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
    J Clin Invest. 2022 Sep 1. pii: 160152. doi: 10.1172/JCI160152.
    PubMed     Abstract available


  30. WANG H, Lin Z, Nian Z, Zhang W, et al
    Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    August 2022
  31. HE Y, Luo W, Liu Y, Wang Y, et al
    IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
    J Clin Invest. 2022 Aug 25. pii: 157917. doi: 10.1172/JCI157917.
    PubMed     Abstract available


    June 2022
  32. YAN D, Huelse JM, Kireev D, Tan Z, et al
    MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    J Clin Invest. 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.
    PubMed     Abstract available


  33. DEFAYE M, Iftinca MC, Gadotti VM, Basso L, et al
    The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    May 2022
  34. NANJO S, Wu W, Karachaliou N, Blakely CM, et al
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
    J Clin Invest. 2022 May 17. pii: 145099. doi: 10.1172/JCI145099.
    PubMed     Abstract available


    April 2022
  35. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    March 2022
  36. XU C, Jin G, Wu H, Cui W, et al
    SIRPgamma-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    February 2022
  37. MANABE T, Bivona TG
    Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


  38. TSAI YS, Woodcock MG, Azam SH, Thorne LB, et al
    Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    November 2021
  39. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    October 2021
  40. ZHANG W, Sun Y, Bai L, Zhi L, et al
    RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11.
    J Clin Invest. 2021 Oct 5. pii: 152067. doi: 10.1172/JCI152067.
    PubMed     Abstract available


    September 2021
  41. HEISHIMA K, Sugito N, Soga T, Nishikawa M, et al
    Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    August 2021
  42. SU SF, Ho H, Li JH, Wu MF, et al
    DNA methylome and transcriptome landscapes of cancer-associated fibroblasts reveal a smoking-associated malignancy index.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    May 2021
  43. MAIMON A, Levi-Yahid V, Ben-Meir K, Halpern A, et al
    Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  44. LIANG W, Chen Z, Li C, Liu J, et al
    Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    January 2021
  45. SEHGAL K, Barbie DA
    Targeting the mutant p53 secretome.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  46. AMOEDO ND, Sarlak S, Obre E, Esteves P, et al
    Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  47. CHO J, Min HY, Lee HJ, Hyun SY, et al
    RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  48. TAN X, Shi L, Banerjee P, Liu X, et al
    A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.